Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$132M |
| 2 |
Newmont
NEM
|
+$67.7M |
| 3 |
Corteva
CTVA
|
+$65.9M |
| 4 |
Amcor
AMCR
|
+$58.2M |
| 5 |
Alibaba
BABA
|
+$48.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$128M |
| 2 |
Apple
AAPL
|
+$93M |
| 3 |
GG
Goldcorp Inc
GG
|
+$78.3M |
| 4 |
Microsoft
MSFT
|
+$73.5M |
| 5 |
Pfizer
PFE
|
+$52.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.91% |
| 2 | Healthcare | 14.68% |
| 3 | Consumer Discretionary | 11.95% |
| 4 | Communication Services | 10.15% |
| 5 | Industrials | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Corcept Therapeutics
CORT
$12.3B
| $2.14M | ﹤0.01% |
192,100
+2,700
| +1% | +$30.1K |
|
|
ADAM
1652
Adamas Trust
ADAM
$919M
| $2.14M | ﹤0.01% |
86,330
+2,200
| +3% | +$54.3K |
|
1653
AtriCure
ATRC
$2.17B
| $2.14M | ﹤0.01% |
71,700
+8,500
| +13% | +$248K |
|
1654
Innovative Industrial Properties
IIPR
$1.69B
| $2.14M | ﹤0.01% |
+17,300
| New | +$1.59M |
|
1655
Interparfums
IPAR
$3.83B
| $2.13M | ﹤0.01% |
32,100
+700
| +2% | +$48.9K |
|
|
BIG
1656
DELISTED
Big Lots, Inc.
BIG
| $2.13M | ﹤0.01% |
74,506
+1,000
| +1% | +$33.4K |
|
|
KNL
1657
DELISTED
Knoll, Inc.
KNL
| $2.13M | ﹤0.01% |
92,500
+2,500
| +3% | +$51.8K |
|
|
TGI
1658
DELISTED
Triumph Group
TGI
| $2.13M | ﹤0.01% |
92,800
+2,000
| +2% | +$43K |
|
|
NP
1659
DELISTED
Neenah, Inc. Common Stock
NP
| $2.12M | ﹤0.01% |
31,400
+700
| +2% | +$44.2K |
|
1660
Huron Consulting
HURN
$2.45B
| $2.12M | ﹤0.01% |
42,000
+900
| +2% | +$44K |
|
|
AQUA
1661
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
| $2.12M | ﹤0.01% |
148,600
+13,500
| +10% | +$175K |
|
1662
Garrett Motion
GTX
$5.46B
| $2.11M | ﹤0.01% |
137,700
+2,800
| +2% | +$47.5K |
|
1663
OR Royalties Inc
OR
$6.28B
| $2.11M | ﹤0.01% |
202,830
-10,300
| -5% | -$109K |
|
|
PRFT
1664
DELISTED
Perficient Inc
PRFT
| $2.11M | ﹤0.01% |
61,600
| – | – |
|
1665
Coherus Oncology
CHRS
$185M
| $2.1M | ﹤0.01% |
94,900
+14,300
| +18% | +$248K |
|
|
ESPR
1666
DELISTED
Esperion Therapeutics
ESPR
| $2.09M | ﹤0.01% |
44,900
+900
| +2% | +$42.3K |
|
1667
Patrick Industries
PATK
$2.82B
| $2.09M | ﹤0.01% |
63,713
+1,950
| +3% | +$61.1K |
|
1668
Tompkins Financial
TMP
$1.42B
| $2.09M | ﹤0.01% |
25,600
+600
| +2% | +$47.6K |
|
1669
Apogee Enterprises
APOG
$907M
| $2.08M | ﹤0.01% |
48,000
-3,400
| -7% | -$133K |
|
1670
Tilray
TLRY
$622M
| $2.08M | ﹤0.01% |
+4,470
| New | +$2.14M |
|
|
BAND
1671
Bandwidth Inc
BAND
$1.71B
| $2.08M | ﹤0.01% |
+27,700
| New | +$2.02M |
|
|
CLDR
1672
DELISTED
Cloudera, Inc.
CLDR
| $2.08M | ﹤0.01% |
394,813
+10,700
| +3% | +$98.7K |
|
|
SYKE
1673
DELISTED
SYKES Enterprises Inc
SYKE
| $2.08M | ﹤0.01% |
75,623
+1,600
| +2% | +$43.1K |
|
|
ODP
1674
DELISTED
ODP
ODP
| $2.07M | ﹤0.01% |
100,660
+10,910
| +12% | +$247K |
|
|
VBTX
1675
DELISTED
Veritex Holdings
VBTX
| $2.07M | ﹤0.01% |
79,917
-3,100
| -4% | -$80.3K |
|
Similar funds
Swiss National Bank's Q2 2019 Portfolio in Review
As of Q2 2019, Swiss National Bank held 2,619 positions worth $92.7B, up 1.7% from $91.2B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Swiss National Bank's Q2 2019 filing shows 112 new, 1,554 increased, 696 reduced and 65 closed positions. Its largest new stake was Dow Inc: 2,494,044 shares worth $123M. The largest sale was DuPont de Nemours, an estimated $128M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2019 buy was Dow Inc: 2,494,044 shares worth $123M.
- Swiss National Bank added most to Newmont in Q2 2019, an estimated $67.7M increase.
- Swiss National Bank's biggest Q2 2019 reduction was DuPont de Nemours, cutting an estimated $128M.
- Swiss National Bank fully exited Goldcorp Inc in Q2 2019, selling an estimated $78.3M.
- Swiss National Bank's ten largest holdings make up 18% of its $92.7B portfolio in Q2 2019.
- Swiss National Bank opened 112 new positions and closed 65 in Q2 2019.
- Swiss National Bank's portfolio value rose 1.7% quarter-over-quarter to $92.7B.
Based on Swiss National Bank's 13F filing for Q2 2019, filed 2 Aug 2019.